Evoke Pharma Statistics
Total Valuation
Evoke Pharma has a market cap or net worth of $5.17 million. The enterprise value is -$2.30 million.
Important Dates
The next estimated earnings date is Tuesday, August 12, 2025, before market open.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Evoke Pharma has 2.02 million shares outstanding. The number of shares has increased by 491.05% in one year.
| Current Share Class | 1.49M |
| Shares Outstanding | 2.02M |
| Shares Change (YoY) | +491.05% |
| Shares Change (QoQ) | -26.66% |
| Owned by Insiders (%) | 0.99% |
| Owned by Institutions (%) | 5.19% |
| Float | 1.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.55 |
| Forward PS | 0.40 |
| PB Ratio | 0.94 |
| P/TBV Ratio | 0.89 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.55, with a Debt / Equity ratio of 0.88.
| Current Ratio | 1.55 |
| Quick Ratio | 1.45 |
| Debt / Equity | 0.88 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.01 |
Financial Efficiency
Return on equity (ROE) is -108.77% and return on invested capital (ROIC) is -32.11%.
| Return on Equity (ROE) | -108.77% |
| Return on Assets (ROA) | -21.70% |
| Return on Invested Capital (ROIC) | -32.11% |
| Return on Capital Employed (ROCE) | -84.47% |
| Revenue Per Employee | $3.86M |
| Profits Per Employee | -$1.69M |
| Employee Count | 3 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 0.55 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.49% in the last 52 weeks. The beta is 0.02, so Evoke Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.02 |
| 52-Week Price Change | -60.49% |
| 50-Day Moving Average | 3.02 |
| 200-Day Moving Average | 4.09 |
| Relative Strength Index (RSI) | 39.08 |
| Average Volume (20 Days) | 18,742 |
Short Selling Information
The latest short interest is 17,702, so 0.88% of the outstanding shares have been sold short.
| Short Interest | 17,702 |
| Short Previous Month | 20,909 |
| Short % of Shares Out | 0.88% |
| Short % of Float | 1.34% |
| Short Ratio (days to cover) | 1.01 |
Income Statement
In the last 12 months, Evoke Pharma had revenue of $11.59 million and -$5.08 million in losses. Loss per share was -$2.16.
| Revenue | 11.59M |
| Gross Profit | 11.29M |
| Operating Income | -5.00M |
| Pretax Income | -7.13M |
| Net Income | -5.08M |
| EBITDA | n/a |
| EBIT | -5.00M |
| Loss Per Share | -$2.16 |
Full Income StatementBalance Sheet
The company has $12.62 million in cash and $5.14 million in debt, giving a net cash position of $7.48 million or $3.70 per share.
| Cash & Cash Equivalents | 12.62M |
| Total Debt | 5.14M |
| Net Cash | 7.48M |
| Net Cash Per Share | $3.70 |
| Equity (Book Value) | 5.84M |
| Book Value Per Share | 2.89 |
| Working Capital | 5.78M |
Full Balance SheetCash Flow
| Operating Cash Flow | -3.88M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is 97.36%, with operating and profit margins of -43.17% and -43.80%.
| Gross Margin | 97.36% |
| Operating Margin | -43.17% |
| Pretax Margin | -43.80% |
| Profit Margin | -43.80% |
| EBITDA Margin | n/a |
| EBIT Margin | -43.17% |
| FCF Margin | n/a |
Dividends & Yields
Evoke Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -491.05% |
| Shareholder Yield | -491.05% |
| Earnings Yield | -98.14% |
| FCF Yield | n/a |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 1, 2024. It was a reverse split with a ratio of 0.0833333:1.
| Last Split Date | Aug 1, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.0833333:1 |
Scores
Evoke Pharma has an Altman Z-Score of -10.55 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.55 |
| Piotroski F-Score | 4 |
